Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
VLST, a Seattle biotech company that raised about $50 million in its nine-year history, has wound down all its operations and sold off its remaining assets, Xconomy has learned. The names of the buyers, and the price they paid for VLST’s components, aren’t being disclosed, said VLST’s former CEO Marty Simonetti. One buyer has scooped up an antibody drug candidate for cancer that’s being prepped for mid-stage clinical trials.
Help employers find you! Check out all the jobs and post your resume.
VLST, a Seattle biotech company that raised about $50 million in its nine-year history, has wound down all its operations and sold off its remaining assets, Xconomy has learned. The names of the buyers, and the price they paid for VLST’s components, aren’t being disclosed, said VLST’s former CEO Marty Simonetti. One buyer has scooped up an antibody drug candidate for cancer that’s being prepped for mid-stage clinical trials.
Help employers find you! Check out all the jobs and post your resume.
